Vesique® (APL-1202)
Non-Muscle Invasive Bladder Cancer (NMIBC)
Key Facts
About Asieris Pharmaceuticals
Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.
View full company profileAbout Asieris Pharmaceuticals
Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.
View full company profileAbout Asieris Pharmaceuticals
Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| FL115 | Forlong Biotechnology | Phase 2 |
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Pre-clinical/Phase 1 |
| DPX-formulated Products | BioVaxys | Phase 1 |
| Alpha1H | Hamlet Biopharma | Phase 2 |
| LiPax | LIPAC Oncology | Phase 2 |
| VAX014 | Vaxiion Therapeutics | Phase 1/2 |
| ZH9 | Prokarium | Phase 1 |
| Dabogratinib (Onc) | Tyra Biosciences | Phase 1/2 |
| NDV-01 | Relmada Therapeutics | Phase 2/3 |
| VDC Platform | Aura Biosciences | Preclinical |